Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation Englewood Cliffs NJ, Feb. 03, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTC QB: SILO), a developmental stage biopharmaceutical company, today announced that it has extended its exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as…


Previous articleMydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member
Next articleReligious Practice Under Oregon Measure 109